Fig. 4: Schematic of the process used for the manufacture and administration of T cell therapy. | Nature Communications

Fig. 4: Schematic of the process used for the manufacture and administration of T cell therapy.

From: Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years

Fig. 4: Schematic of the process used for the manufacture and administration of T cell therapy.

Peripheral blood mononuclear cells (PBMC) isolated from the peripheral blood of healthy volunteers were stimulated with selected viral peptide epitopes and then cultured for 14 to 17 days in the presence of  IL-2. Subsequently, virus-specific T cells were assessed for antigen-specific reactivity and stored as a cryogenic bank. Virus-specific T cells were matched with appropriate patients based on HLA class I and class II alleles as outlined in the material and methods section. (created with BioRender.com under a paid subscription).

Back to article page